{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:17:13Z","timestamp":1761884233759,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.reumae.2022.10.002","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T07:40:26Z","timestamp":1683099626000},"page":"279-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Mar\u00eda Lorena","family":"Brance","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Silvia","family":"Larroud\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Somma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelina","family":"Giacoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Galich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Agust\u00edn","family":"Ramirez Stieben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Cielo","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"De La Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariana","family":"Ringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas R.","family":"Brun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2022.10.002_bib0260","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1359\/JBMR.050304","article-title":"Predictive value of BMD for hip and other fractures","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.reumae.2022.10.002_bib0265","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.reumae.2022.10.002_bib0270","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5","article-title":"Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis","volume":"44","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.10.002_bib0275","unstructured":"Working group in collaboration with The Royal College of Physicians, The Bone and Tooth Society of Great Britain, and The National Osteoporosis Society. Glucocorticoid-induced osteoporosis. 2002."},{"key":"10.1016\/j.reumae.2022.10.002_bib0280","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2022.10.002_bib0285","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jbmr.362","article-title":"Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"26","author":"Hansen","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.reumae.2022.10.002_bib0290","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0295","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2022.10.002_bib0300","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11657-021-00902-z","article-title":"Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)","volume":"16","author":"Pereira","year":"2021","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.reumae.2022.10.002_bib0305","first-page":"11","article-title":"A longitudinal study of diagnosis and treatment for glucocorticoid-induced osteoporosis","volume":"11","author":"Tanaka","year":"2003","journal-title":"Osteoporosis Jpn"},{"key":"10.1016\/j.reumae.2022.10.002_bib0310","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.reumae.2022.10.002_bib0320","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2022.10.002_bib0325","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJM199306173282404","article-title":"Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin","volume":"328","author":"Sambrook","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2022.10.002_bib0330","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s00774-020-01091-4","article-title":"Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)","volume":"38","author":"Matsumoto","year":"2020","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.reumae.2022.10.002_bib0335","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2022.10.002_bib0340","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.10.002_bib0345","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","article-title":"Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Lems","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1479-8077.2007.00249.x","article-title":"The bone mineral density effects of calcitonin in and alendronate combined therapy in patients with rheumatoid arthritis","volume":"10","author":"Ozoran","year":"2007","journal-title":"APLAR J Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0355","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3899\/jrheum.081207","article-title":"Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial","volume":"36","author":"Stoch","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0360","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/archdermatol.2011.354","article-title":"Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study","volume":"148","author":"Tee","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"de Nijs","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2022.10.002_bib0370","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2036.2008.03899.x","article-title":"Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis","volume":"29","author":"Kitazaki","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.reumae.2022.10.002_bib0375","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/s10165-008-0055-y","article-title":"Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol","volume":"18","author":"Takeda","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0380","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980070122","article-title":"Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients","volume":"11","author":"Eastell","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0385","first-page":"1","article-title":"Efficacy and safety of sodium RISedronate for glucocorticoid-induced OstTeoporosis with rheumaTOid arthritis (RISOTTO study): a multicentre, double-blind, randomized, placebo-controlled trial","volume":"2","author":"Fujieda","year":"2020","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0390","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1248\/yakushi.127.1491","article-title":"Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients","volume":"127","author":"Yamada","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.reumae.2022.10.002_bib0395","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.10.002_bib0400","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.reumae.2022.10.002_bib0405","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0410","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/03009742.2012.664647","article-title":"Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial","volume":"41","author":"Hakala","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0415","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clinthera.2017.01.008","article-title":"Monthly oral ibandronate reduces bone loss in Korean women with rheumatoid arthritis and osteopenia receiving long-term glucocorticoids: a 48-week double-blinded randomized placebo-controlled investigator-initiated trial","volume":"39","author":"Shin","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.reumae.2022.10.002_bib0420","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0425","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial","volume":"61","author":"Boutsen","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0430","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone","volume":"16","author":"Boutsen","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.reumae.2022.10.002_bib0435","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2022.10.002_bib0440","doi-asserted-by":"crossref","first-page":"e0193846","DOI":"10.1371\/journal.pone.0193846","article-title":"The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial","volume":"13","author":"Iseri","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.reumae.2022.10.002_bib0445","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study","volume":"6","author":"Saag","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0450","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0455","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2022.10.002_bib0460","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00198-009-0917-y","article-title":"Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status","volume":"20","author":"Langdahl","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0465","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.10.002_bib0470","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.reumae.2022.10.002_bib0475","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1002\/art.21477","article-title":"Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study","volume":"52","author":"Mok","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.10.002_bib0480","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.10.002_bib0485","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00774-004-0596-x","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004)","volume":"23","author":"Nawata","year":"2005","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.reumae.2022.10.002_bib0490","first-page":"863","article-title":"Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune diseases","volume":"32","author":"Kumagai","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.10.002_bib0495","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1507\/endocrj.53.27","article-title":"The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis","volume":"53","author":"Kaji","year":"2006","journal-title":"Endocr J"},{"key":"10.1016\/j.reumae.2022.10.002_bib0500","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","article-title":"A systematic review of hip fracture incidence and probability of fracture worldwide","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0505","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","article-title":"Case finding for the management of osteoporosis with FRAX \u2013 assessment and intervention thresholds for the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.reumae.2022.10.002_bib0510","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","article-title":"Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA","volume":"19","author":"Dawson-Hughes","year":"2008","journal-title":"Osteoporos Int"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574323000515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574323000515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:04:04Z","timestamp":1761879844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574323000515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2173574323000515"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2022.10.002","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2022.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}